

Ben Page, Chief Executive Officer Dan Lévy, Chief Financial Officer

July 25<sup>th</sup>, 2024



### **TOTAL GROWTH OF 4.7% GOOD PROFITABILITY & CASH GENERATION**

**REVENUE** 

€1,139м

TOTAL **GROWTH** 

+4.7%

**ORGANIC GROWTH** 

of which Q2: +3.1%

**SCOPE EFFECT FX EFFECT** 

**+3.8**% **+2.8**% **-1.8**%

**PROFITABILITY** 

**10.1%** vs 8.7% in H1 2023

FREE CASH FLOW

**€80**M vs €24m in H12023



## MIXED SITUATION IN THE US

#### H1 organic growth

US

**-2.2**%

#### **STRENGTHS**

Solid performance in CPG

Strong growth in Ipsos Digital

Recovery and moderate growth in Big Tech clients

#### **CHALLENGES**

Electoral cycle and end of major one-off contracts weighing on our Public Affairs activity

Wave of restructuring by major players in the Pharma industry

#### **NEW CEO AND MANAGEMENT ORGANIZATION IN NORTH AMERICA**

Stabilization in H2 and return to growth expected by the beginning of next year





# REVENUE BREAKDOWN BY REGION

In millions of euros	H1 2024	Share	Total growth	Organic growth
EMEA	523.3	46%	10.0%	7.6%
Americas	418.7	37%	-0.6%	-0.6%
Asia-Pacific	196.5	17%	3.4%	4.0%
Total	1,138.5	100%	4.7%	3.8%

5



# REVENUE BREAKDOWN BY AUDIENCE

In millions of euros	H1 2024	Share	Total growth	Organic growth
Consumers <sup>1</sup>	562.3	50%	7.6%	8.0%
Clients and employees <sup>2</sup>	230.3	20%	-0.3%	0.5%
Citizens <sup>3</sup>	182.3	16%	10.9%	1.1%
Doctors and patients <sup>4</sup>	163.7	14%	-3.1%	-2.5%
Total	1,138.5	100%	4.7%	3.8%

Breakdown of each Service Line by segment: breakdown of revenue by audience segment is non-financial data, likely to change over time depending on changes to the organization of Ipsos teams.



© Ipsos | Half-Year Results 2024


<sup>1.</sup> Brand Health Tracking, Creative Excellence, Innovation, Ipsos UÚ, Ipsos MMA, Market Strategy & Understanding, Observer (excl. public sector), Ipsos Synthesio, Strategy3

<sup>2.</sup> Automotive & Mobility Development, Audience Measurement, Customer Experience, Channel Performance (including Mystery Shopping and Shopper), Media development, ERM, Capabilities

<sup>3.</sup> Public Affairs, Corporate Reputation

<sup>4.</sup> Pharma (quantitative and qualitative)

# **REVENUE BY SECTOR**





# STRONG GROWTH IN NEW SERVICES



ORGANIC GROWTH +13%

SHARE OF TOTAL REVENUE

Of which IPSOS DIGITAL

+37%

21.5%



## **GOOD PROFITABILITY**

In millions of euros	June 30, 2024	June 30, 2023	% Change	December 31, 2023
Revenue	1,138.5	1,087.1	+4.7%	2,389.8
Gross margin	780.1	736.1	+6.0%	1,612.8
Gross margin / revenue	68.5%	67.7%		67.5%
Operating margin	115.1	94.3	+22.1%	312.4
Operating margin / revenue	10.1%	8.7%		13.1%
Net profit attributable to the Group	78.0	56.4	+38.3%	159.7
Adjusted net profit* attributable to the Group	82.3	70.1	+17.5%	228.6

<sup>\*</sup> Adjusted net profit is calculated before non-cash items covered by IFRS 2 (share-based compensation), before amortization of acquisition-related intangible assets (customer relationships), before deferred tax liabilities related to goodwill for which amortization is deductible in some countries and before the impact net of tax of other non-recurring income and expenses.



© Ipsos | Half-Year Results 2024

# **GOOD CASH GENERATION**

In millions of euros	June 30, 2024	June 30, 2023	December 31, 2023
Gross operating cashflow	177.3	137.0	412.9
Change in WCR	7.1	(28.3)	(65.2)
Income tax paid	(49.0)	(34.1)	(63.4)
Property, plant and equipment, intangible & financial assets	(32.7)	(28.8)	(61.6)
Net interest paid	(1.2)	(1.7)	(12.3)
Lease payments	(21.6)	(20.4)	(41.5)
Free cash flow	79.9	23.7	168.8
Acquisitions and financial investments	(28.2)	(6.1)	(47.9)
Purchase / Sale of shares	(38.7)	(63.6)	(85.5)
Net change in long-term borrowings	(20.0)	(29.6)	(57.5)
Dividends	0.0	0.0	(59.0)
Cash position at end of period	282.5	300.8	277.9




© Ipsos | Half-Year Results 2024

# STRONG FINANCIAL POSITION

In millions €	June 30, 2024	June 30, 2023	December 31, 2023
Equity	1,421	1,359	1,433
Net debt*	100	129	120
Net debt / EBITDA**	X 0.3	x 0.4	X 0.3

Gross debt: 377 m€



**Liquidity**: Close to **€500m** of undrawn credit lines with maturities > 1 year




<sup>\*</sup>Bonds and bank loans net of cash

<sup>\*\*</sup> Excluding IFRS 16 impact



## **GROWING NUMBER OF NEW GEN AI SOLUTIONS**

12 solutions in the 2024 roadmap, including:



Powered by

13

**Ipsos Facto** 





Ad evaluation solution generating actionable insights within minutes

- Predicts human reactions to TV and social video ads, by combining Human Intelligence with Artificial Intelligence
- Enables to quickly draw learnings on ads effectiveness
- Powered by Ipsos Facto and based on 18,000 human response cases

Watch the launch video





Al-powered solution to enhance segmentation research

- Allows clients to converse with personas representing their target segments
- Supports faster decision-making on brand positioning, communication, innovation, etc.
- Powered by Ipsos Facto, based on segmentation survey data, and developed for consumer & healthcare segmentations



Creation of personas enabling to test clients' reactions regarding low carbon solutions



# SIGNALS GEN AI

ADOPTED BY HP

 Our Generative Al solution transforms millions of social data signals into insights in < 60 seconds</li>

 2,000 ratings and review products on 9 markets and 4 categories

Trend detection, competitive benchmarking and innovation

"You provided the insight that people want to save time to be able to focus on the more strategic, creative and fulfilling work. That's going to fuel our strategy."

Head of Marketing and Insight at HP





### OUTLOOK

- Continued growth
- Successful acquisitions
- Good profitability, cash generation and strong financial position
- Active implementation of our Tech roadmap
- Strengthened managerial organization to face headwinds in North America
- Guidance adjusted downwards on organic growth and maintained on operating margin
- New strategic review: Horizon 2030

**ORGANIC GROWTH** 

Close to that of last year (+3%)

18

OPERATING MARGIN

~13%





Q&A session
Online via the platform or by phone

Please find below the dial-in phone numbers:

France: +33 170 9187 04

UK: +44 1212818004

US: +17187058796

The password to access

the call is "**lpsos**"

